VIM and non-small cell lung carcinoma: Non-small cell lung cancer (NSCLC) cell lines sensitive to gefitinib express EMT markers such as E-cadherin, claudin-4 and claudin-7, but resistant cell lines have lost expression of these genes, while the mesenchymal marker vimentin was highly expressed in the resistant cell lines (Frederick et al., 2007).